Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity was posted on December 9, 2010. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development

Closed
BARDA_BAA_11-100-SOL-00001Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.
Mrpbs Minneapolis Mn

POSTED

20 days ago

DEADLINE

in 20 days

General Info

Agency

N/A

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

1 update
PhaseClosed
Posted

Presolicitation

Notice updated

The notice description changed. The point of contact changed.

Type Changed

Presolicitation → Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts2 people available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Michael A. YounkinsContracting Officer
Wayne A. MedinaContract Specialist

Full Description

Show more
BARDA - Strategic Science and Technology Division Broad Agency Announcement Synopsis Notice Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development The Office of Acquisition Management Contracts & Grants (AMCG) with the office of Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. BARDA/AMCG's mission includes managing the advanced research and development of medical countermeasures (MCM) for chemical, biological, radiological, and nuclear agents (CBRN), as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield. Preparedness mission and priorities are articulated in the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Implementation Plan for CBRN Threats and the National Strategy for Pandemic Influenza. The implementation plans are located on the Assistant Secretary for Preparedness and Response (ASPR) website http://www.phe.gov/preparedness/pages/default.aspx and the National Strategy for Pandemic Influenza on the website http://www.pandemicflu.gov. The Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development, (ii) research on and development of research tools and other devices and technologies, and (iii) research to promote strategic initiatives. Through this Broad Agency Announcement (BAA), BARDA seeks to advance the technological and scientific advancements of medical countermeasures for biodefense and emerging infectious disease threats, including pandemic influenza. The PAHPA is located on the ASPR website http://www.phe.gov/Preparedness/legal/pahpa/pages/default.aspx. This BAA is a continuation of a previous BAA (BARDA-BAA-09-100-SOL-0010) and is similarly designed to promote science and technology advancements of platforms applied to MCM development for the Strategic Science and Technology Division (SST) of BARDA/AMCG and will be open to all responsible Offerors. The Government's intent is to solicit potential advancements in science and technology in the following BARDA SST Areas of Interest: 1. Technologies to accelerate evaluation of vaccines and therapeutics. 2. Formulation chemistry, protein stabilization, and vaccine delivery technologies. 3. Innovative methods in bioprocess development and manufacturing. 4. Methods and technologies to advance development of tests for rapid diagnosis of human injury and infection. The BARDA SST Areas of Interest are designed to target platform technologies focused on (1) product improvements to enhance the safety, efficacy, and ease of use of MCM, (2) reducing time and cost of MCM development, evaluation, and manufacturing, and (3) development of innovative diagnostic platforms for the rapid diagnosis of priority pathogens. The specific application of the technologies will focus on biodefense, pandemic influenza, and other emerging infectious diseases (EID). BARDA is open to evaluation of technologies at multiple stages of product development. BARDA anticipates that demonstrating utility of these novel platform technologies will generate validated data suitable for comparability analysis with candidate products and have direct application to commercial-scale manufacturing or testing processes. The development activities are to be fully integrated with regulatory activities associated with product development efforts. BARDA anticipates awarding multiple contracts, grants, cooperative agreements, and/or other transactions for research and development efforts from this BAA that have sufficient potential for success, are of interest to the Government, and support one or more of the listed BARDA SST Areas of Interest. Please contact the Contracting Officer for additional information. Point of Contact(s): Carolyn Keeseman, Contracting Officer Phone: 202-260-0950 Fax: 202-205-0613 Email: Carolyn.Keeseman@hhs.gov Elizabeth Elmazahi, Contract Specialist (Alternate) Phone: 202-205-8926 Fax: 202-205-6061 Email: Elizabeth.Elmazahi@hhs.gov Contracting Office Address: Department of Health and Human Services, Office of the Secretary, Assistant Secretary for Preparedness and Response, Acquisitions Management, Contracts, and Grants, 330 Independence Avenue, SW, Rm G640, Washington, DC, 20201, USA 2/28/2011 Amended the POC and POC Alternate Individuals to Carolyn Keeseman, Contracting Officer and Elizabeth Elmazahi with respective contact information.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS